HC Wainwright Predicts Higher Earnings for Integra Resources
Equities researchers at HC Wainwright raised their FY2025 earnings per share estimates for shares of Integra Resources in a ...
HC Wainwright Cuts Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target to $11.00
Acumen Pharmaceuticals (NASDAQ:ABOS – Free Report) had its price target trimmed by HC Wainwright from $15.00 to $11.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage ...
Co-Diagnostics price target lowered to $1 from $1.50 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Co-Diagnostics (CODX) to $1 from $1.50 and keeps a Neutral rating on the shares following ...
TipRanks on MSN2d
Milestone CRL affirms integrity of clinical data, says H.C. Wainwright
H.C. Wainwright keeps a Buy rating on Milestone Pharmaceuticals (MIST) after the company announced receipt of a complete response letter from the ...
Acumen price target lowered to $11 from $15 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Acumen (ABOS) to $11 from $15 and keeps a Buy rating on the shares. The firm says completion ...
Co-Diagnostics targets 2025 clinical evaluations for TB and HPV tests in India and South Africa
Diagnostics' Q4 2024 earnings insights, FDA resubmissions, TB & HPV test pipelines, and international market growth plans.
TMCnet3d
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high ...